Ottobock Acquires Fesia Technology to Expand Neurorehabilitation Portfolio

The acquisition adds functional electrical stimulation technology to Ottobock’s neuro-orthotics offering, strengthening its position in the growing neurological devices market.

German medical device company Ottobock has agreed to acquire Spanish medtech firm Fesia Technology, expanding its neuro-orthotics portfolio with a range of functional electrical stimulation (FES) products designed to support mobility and rehabilitation.

The transaction, which is expected to close within six months, will see Ottobock take ownership of Fesia’s portfolio of wearable FES devices used to support patients recovering from neurological conditions including stroke, multiple sclerosis (MS) and cerebral palsy.

Financial terms of the acquisition were not disclosed.

Expanding Access to Functional Electrical Stimulation

Fesia Technology develops wearable FES orthoses that use electrical pulses to stimulate weakened muscles, helping patients restore movement by encouraging the formation of new neural pathways.

The company’s technology is designed to support people living with movement impairments caused by neurological disorders and injuries.

Fesia’s product portfolio includes:

• Fesia Walk – a device designed to address foot drop by stimulating muscles involved in walking.

• Fesia Grasp – an upper limb orthosis designed to support hand function by targeting multiple muscle groups.
  

The systems are controlled through the Fesia Pro smartphone application, allowing clinicians to customise stimulation parameters based on individual patient requirements.

Strengthening Ottobock’s Neuro-Orthotics Strategy

The acquisition complements Ottobock’s existing neurorehabilitation portfolio, which includes the Exopulse Mollii Suit, a full-body neuromodulation system designed to reduce muscle spasticity and pain through electrical stimulation.

By integrating Fesia’s FES platform, Ottobock aims to broaden its ability to support patients across different stages of neurological rehabilitation.

Fesia CEO Haritz Zabaleta said the partnership would allow the company to scale its technology globally and accelerate innovation in neurorehabilitation and human mobility.

Growing Demand for Neurological Technologies

The acquisition comes as demand for neurological devices continues to increase worldwide.

Neurological disorders are currently the leading cause of disability globally and represent one of the largest healthcare challenges facing health systems.

Industry analysis projects that the global neurology devices market will exceed $25 billion by 2034, driven by rising disease prevalence and increasing demand for advanced rehabilitation technologies.

A 2024 World Health Organization report found that the overall health burden associated with neurological conditions has increased significantly since 1990, with access to specialist care remaining a challenge in many regions.

Supporting Future Mobility Solutions

Ottobock CEO Oliver Jakobi highlighted the growing number of people affected by neurological conditions and said improving care pathways for these patients remains a core focus for the company.

The acquisition provides Ottobock with an established FES technology platform that can be integrated into its wider mobility ecosystem.

By combining assistive devices, rehabilitation technologies and digital tools, Ottobock is positioning itself to play a larger role in the evolving neurological care market.

Why the Acquisition Matters

The deal reflects several broader trends shaping medical device innovation:

• Neurorehabilitation technologies are becoming increasingly important as neurological disease burden rises.

• Functional electrical stimulation is gaining traction as a non-invasive approach to restoring mobility.

• Medtech companies are expanding beyond traditional devices into integrated rehabilitation platforms.

• Demand is increasing for personalised solutions that support long-term patient recovery.
  

Summary

Ottobock has agreed to acquire Fesia Technology, adding wearable functional electrical stimulation devices to its neuro-orthotics portfolio.

The acquisition strengthens Ottobock’s position in neurological rehabilitation and supports its broader strategy of developing technologies aimed at improving mobility and independence for patients living with neurological conditions.